Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic CAR T Cell Persistence

The European Patent Office granted Allogene Therapeutics intellectual property protection for methods relating to CAR-T cell therapy. The patent covers selective targeting of host CD70+ alloreactive cells to improve the persistence of allogeneic CAR T cells. This patent grant establishes exclusive rights in designated European states for the applicant.\n\nFor pharmaceutical and biotechnology companies developing allogeneic CAR-T cell therapies, this patent may affect freedom to operate in the European market. Competitors may need to obtain licenses or design around the claimed methods. This represents a routine IP event that strengthens the patent portfolio of Allogene Therapeutics in the cell therapy space.